



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2011

Chemistry and biology of mammalian metallothioneins

Vašák, M ; Meloni, G

DOI: <https://doi.org/10.1007/s00775-011-0799-2>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-49999>

Journal Article

Published Version

Originally published at:

Vašák, M; Meloni, G (2011). Chemistry and biology of mammalian metallothioneins. *Journal of Biological Inorganic Chemistry*, 16(7):1067-1078.

DOI: <https://doi.org/10.1007/s00775-011-0799-2>

Chemistry and biology of mammalian metallothioneins

Milan Vašák · Gabriele Meloni

Received: 30 March 2011 / Accepted: 12 May 2011 / Published online: 7 June 2011
© SBIC 2011

Abstract Metallothioneins (MTs) are a class of ubiquitously occurring low molecular mass, cysteine- and metal-rich proteins containing sulfur-based metal clusters formed with Zn(II), Cd(II), and Cu(I) ions. In mammals, four distinct MT isoforms designated MT-1 through MT-4 exist. The first discovered MT-1/MT-2 are widely expressed isoforms, whose biosynthesis is inducible by a wide range of stimuli, including metals, drugs, and inflammatory mediators. In contrast, MT-3 and MT-4 are noninducible proteins, with their expression primarily confined to the central nervous system and certain squamous epithelia, respectively. MT-1 through MT-3 have been reported to be secreted, suggesting that they may play different biological roles in the intracellular and extracellular space. Recent reports established that these isoforms play an important protective role in brain injury and metal-linked

neurodegenerative diseases. In the postgenomic era, it is becoming increasingly clear that MTs fulfill multiple functions, including the involvement in zinc and copper homeostasis, protection against heavy metal toxicity, and oxidative damage. All mammalian MTs are monomeric proteins, containing two metal–thiolate clusters. In this review, after a brief summary of the historical milestones of the MT-1/MT-2 research, the recent advances in the structure, chemistry, and biological function of MT-3 and MT-4 are discussed.

Keywords Zinc · Copper · Mammalian metallothioneins · Metal–thiolate clusters · Neurodegenerative diseases

Introduction

In mammals, four distinct metallothionein (MT) isoforms designated MT-1 through MT-4 exist. The first MT, later found to be composed of the MT-1 and MT-2 isoforms, was discovered more than 50 years ago by Margoshes and Vallee [1] followed by the discovery of MT-3 [2] and MT-4 [3] at the beginning of 1990s. The most predominant isoforms MT-1/MT-2 are expressed in almost all tissues and their biosynthesis is inducible by a variety of stress conditions and compounds, including glucocorticoids, cytokines, reactive oxygen species (ROS), and metal ions [4]. In contrast, MT-3 and MT-4 are relatively unresponsive to these inducers and their expression is primarily confined to the central nervous system (CNS) [5] and cornified and stratified squamous epithelium [3], respectively. Presently, there are a great number of reviews covering different biological and structural aspects of MT research and focusing predominantly on MT-1/MT-2

This article is part of a JBIC special issue on metallothioneins.

M. Vašák · G. Meloni
Department of Biochemistry,
University of Zurich,
Winterthurerstrasse 190,
8057 Zurich, Switzerland

Present Address:

M. Vašák (✉)
Department of Inorganic Chemistry,
University of Zurich,
Winterthurerstrasse 190,
8057 Zurich, Switzerland
e-mail: mvasak@bioc.uzh.ch

G. Meloni
Division of Chemistry and Chemical Engineering and Howard
Hughes Medical Institute,
California Institute of Technology,
Pasadena, CA 91125, USA

[6–16]. In recent years the role of MTs in the brain, in particular of the MT-3 isoform, has been the subject of intense research. The biological studies on brain MTs are reviewed in this special issue. In this contribution, we briefly summarize the historical milestones of MT-1/MT-2 research till about 1990 and focus on the recent advances in the structure, chemistry, and biological functions of MT-3 and MT-4.

Metallothionein-1/metallothionein-2: historical highlights

As discussed by the late Bert L. Vallee [17] in his contribution to the first MT meeting, the discovery of MT has been closely linked with the search for biological material containing cadmium. The first report on the presence of this metal in human organs, in particular kidney, was in the Russian literature in 1941 [18]. In the mid-1950s the translated article became available to Western scientists. Upon screening for cadmium content in kidneys of a few mammalian species, Margoshes and Vallee [1] identified protein containing besides cadmium also a substantial amount of zinc and lesser amounts of copper and iron after fractionation of horse kidney cortex. The purification and characterization of this material by Kägi and Vallee [19] revealed a low molecular mass 6–7-kDa metal- and cysteine-rich protein, named “metallothionein” (MT) to reflect the extremely high thiolate sulfur and metal content, both of the order of 10% (w/w). Further chromatographic separation revealed the presence of two principal MTs, later designated as MT-1 and MT-2, of 61–62 amino acids, of which 20 were cysteines and none of which were aromatic amino acids. Both MTs contained seven Zn(II) or Cd(II)/Zn(II) ions. The subsequent protein sequencing showed a single polypeptide chain with distinct clustering of the 20 cysteine residues into Cys–X–Cys, Cys–Cys and Cys–X–X–Cys sequences, where X stands for amino acids other than cysteine [20] (Table 1). These unique features of the classical mammalian MT-1 and MT-2 isoforms attracted the interest of scientists from fields as different as biochemistry, molecular biology, toxicology, and structural biology.

The toxicology studies were initiated by the finding that MT was present in increased amounts in livers of rabbits

exposed to cadmium. It has been postulated that this observation reflects the induced biosynthesis of this protein by this metal and its role in metal detoxification [22]. This initial assumption of MT-1/MT-2 induction by heavy metals was later confirmed by the increased MT content in liver, kidney, and intestines following the parenteral or dietary administration of cadmium, copper, or zinc to experimental animals [23]. In the years since this publication, a large number of articles on the role of MT-1/MT-2 in metal toxicity have been published and similar conclusions have been drawn. However, the real advances were the observations that mice that cannot synthesize any MT are sensitive to cadmium toxicity, whereas mice that express excess amounts of any MT are resistant to this metal [24–26]. It has been demonstrated, moreover, that selection for cadmium resistance with mammalian cells always results in up to 80-fold increase of the entire MT locus [27]. These observations reflected the original discovery of cadmium-containing MT in horse kidney [1]. Even though cases of cadmium toxicity are known, they are rare and exclusively caused by man. Therefore, it has been suggested that even though a characteristic phenotype of cells and mice with altered expression of MTs is the sensitivity to cadmium toxicity, it seems unlikely that the evolutionary conservation of these ubiquitous, inducible genes in most organisms is driven by the ability of MTs to detoxify cadmium [28]. Thus, the current notion is that cadmium detoxification is a property of MTs rather than its evolutionary function [29].

Molecular biology studies on MTs aimed at the understanding of the gene structure, function, and regulation. The genes for human and mouse MT-1/MT-2 have been most extensively studied [30–33]. Whereas four *MT* genes are present in the mouse genome, in human a significant genetic polymorphism exists. The human *MT* genes are located on band 13 of the long arm of chromosome 16 and are encoded by a multigene cluster of tightly linked genes. There are at least seven functional *MT-1* genes and a single gene encoding the other MT isoforms *MT-2* (*MT-2A*), *MT-3*, and *MT-4* [13]. A number of other *MT* or *MT*-like genes and pseudogenes with significant homology to functional *MT* genes exist within the human genome, but their functionality is unknown. The *MT* genes encode for two-domain proteins. The three exons composing the

Table 1 Alignment of amino acid sequences of the four human metallothionein (MT) isoforms using ClustalW

	1	10	20	30	40	50	60	68
MT-1H	MDPN- CS CEA	GGSC ACAG SC	KCKKCK CTSC	KKSCCS CCPL	GCAKCA QGC I	CKGA -----	SEKCS CCA	
MT-2A	MDPN- CS CAA	GD SCTC AGSC	KCKE CKCTSC	KKSCCS CCPV	GCAKCA QGC I	CKGA -----	SDKCS CCA	
MT-3	MD PETC PCPS	GG SCTC ADSC	KCEG CKCTSC	KKSCCS CCPA	ECEKCA KDCV	CKGG EAAEAE	AEKCS CCQ	
MT-4	MD PREC VCMS	GG ICM CGDNC	KCTT CNCKTC	WKSCCP CCPP	GCAKCA RGC I	CKGG -----	SDKCS CCP	

The conserved cysteine residues are highlighted. The numbering is that of the human MT-3 sequence. Generated with SeaView [21]

human *MT* genes sequentially encode for the N-terminal region of the β -domain (exon 1), the rest of the β -domain (from residue 11 or 12; exon 2), and all of the α -domain (from residue 31 or 32; exon 3). Exons 2 and 3 are spliced at the junction of codons for the Lys/Lys or Arg/Lys residues in the interdomain region. The promoter regions of *MT-1* and *MT-2* genes contain several metal-responsive elements (MREs) and glucocorticoid-responsive elements as well as elements involved in basal level transcription. The *MT-1/MT-2* expression is also regulated by oxidative stress by antioxidant responsive elements or by MREs that are also responsive to oxidants. Metal-regulatory transcription factor 1 (MTF-1), which is essential for basal expression of *MT-1/MT-2* and induction by zinc, binds to promoter proximal MREs. MTF-1 binds to MREs through its six C2H2 zinc fingers [34]. Although similar MREs were also identified in the *MT-3* gene, there were unresponsive to zinc [35]. The DNA sequences responsible for cell-specific regulation of *MT-3* and *MT-4* genes are currently unknown. The regulation of tissue-specific *MT-3* gene expression in humans does not appear to involve a repressor. Thus, other mechanisms such as chromatin organization and epigenetic modifications may account for the presence or absence of *MT-3* transcription.

In early biochemical studies the biological role of *MT-1/MT-2* was sought. As the major zinc-binding proteins in the cell, it has long been hypothesized that MTs can potentially modulate many important biological processes that involve zinc-requiring enzymes. Their involvement can either be direct, via interaction with inactive apoenzymes, or indirect, by regulation of available Zn(II) in the cell. The first demonstration that several zinc-requiring apoenzymes can be reactivated by the transfer of Zn(II) from Zn₇MTs in vitro was 30 years ago [36]. Evidence that apoMT, or thionein, readily removes Zn(II) from zinc-finger transcription factors such as Sp1 and *Xenopus laevis* TFIIIA in vitro, eliminating their DNA binding competence, has also been provided [37, 38]. The in vitro demonstration that MTs are extraordinarily efficient scavengers of free hydroxyl radicals formed during various forms of oxidative stress suggested that these proteins may be a part of such a protective system [39]. The primary targets of the free-radical attack in MTs are thiolate groups of the metal–thiolate clusters, which may be repaired in the cell by reduced glutathione. Following this discovery, evidence supporting such a physiological role of MTs in the cellular defense system against oxidative stress and their induced biosynthesis under these conditions was provided [40]. In the postgenomic era it became clear that MTs can have multiple biological functions.

In view of the high cysteine and metal content, the structural investigations of *MT-1/MT-2* were highly challenging. Since most of these studies were conducted before

1990, no recombinant protein expression systems were available. The native MTs, as isolated from livers of experimental animals, contained either Zn(II) or both Zn(II) and Cd(II) ions. To examine the geometry and the organization of metal binding sites, the native metal ions were replaced by paramagnetic Co(II) or by the NMR-active ¹¹³Cd isotope ($I = 1/2$). The optical and magneto-optical (magnetic circular dichroism) studies of Co₇MT provided evidence for a tetrahedral-type of geometry of all metal binding sites and their coordination by cysteine thiolates [41]. Convincing evidence for the two-cluster arrangement of the seven divalent metal ions in MT, i.e., for a three-metal and a four-metal cluster, has been provided by homonuclear ¹¹³Cd NMR decoupling studies of ¹¹³Cd₇MT. In these studies, the Cd(II) coordination by both terminal and bridging thiolate ligands was inferred from the chemical shift position of the ¹¹³Cd resonances [42]. The observation of an antiferromagnetic coupling between metal centers in electron spin resonance and magnetic susceptibility measurements of Co₇MT lend further support for a cluster structure in MTs [43]. Through enzymatic cleavage of Cd₇MT and the ¹¹³Cd NMR characterization of the Cd₄-containing peptide, the indication for a two-domain structure, each domain encompassing a metal–thiolate cluster, was obtained [44]. The mechanism of metal binding to apoMT-2 was studied by ¹H NMR and magnetic susceptibility measurements of the paramagnetic Co(II) metalloform of the protein at room temperature. The results revealed a detailed binding scheme in which both metal–thiolate clusters in Co₇MT-2 were formed in a noncooperative manner [45]. However, in similar studies using Cd(II), a specific cooperative binding to the α -domain followed by the β -domain was revealed by circular dichroism, magnetic circular dichroism, and ¹¹³Cd NMR measurements [46, 47]. The substantially different metal sizes of Cd(II) and Co(II), the latter being closely similar to that of Zn(II), thiolate affinities, and the corresponding bond lengths may account for the differences in the pathway of cluster formation.

Since early attempts to crystallize *MT-1/MT-2* failed in a number of crystallography groups, a new solution NMR method for the 3D structure determination, developed by Kurt Wüthrich and coworkers in Zurich, was applied. The first structural studies of Wüthrich's group were conducted on Cd₇MT-2 from rabbit liver. However, the structure elucidation by NMR measurements turned out to be more difficult than expected because of the heterogeneity of native protein, the absence of aromatics, leading to very poor chemical shift dispersion, and the presence of Cd–Cys coordinative bonds in the clusters which could not be analyzed with nuclear Overhauser effects. Crucial to the structure elucidation was the preparation of structurally homogeneous ¹¹³Cd₇MT-2 samples, generated through the

method of metal reconstitution, and the development of heteronuclear ^1H – ^{113}Cd correlation experiments enabling the cadmium–cysteine topology of the clusters in the rabbit protein to be unraveled [48].

At about the time of the publication of the cluster topology in rabbit $^{113}\text{Cd}_7\text{MT-2}$, the crystal structure of native rat $\text{Cd}_5\text{Zn}_2\text{MT-2}$ was reported [49]. However, the sequence-specific metal–cysteine coordinative bonds in the crystal structure of the rat protein were substantially different from those found by NMR measurements for the rabbit protein. Given the amount of this covalent connectivity information, it was quite clear that this discrepancy between the two sets of results was not something that could be explained easily. Among others, the most likely reasons considered by the scientific community were (1) the NMR and crystallography results might both be correct as differences in the respective primary structures exist, i.e., the rat protein shows ten substitutions of non-cysteine amino acids, (2) the structural differences were caused by the metal reconstitution of the rabbit protein, and (3) the results obtained using the newly developed NMR technique are presumably incorrect. It is hard to imagine a less desirable event at the early stage in the development of the methodology for NMR structure determination of proteins than that the NMR method should produce a high-profile mistake. Also the structure of $^{113}\text{Cd}_7\text{MT}$ was one of the first protein structures determined by NMR measurements, and it was the first structure of a metalloprotein to be determined. In an effort to resolve the discrepancy, NMR studies aiming at the cluster topology in metal-reconstituted rat $^{113}\text{Cd}_7\text{MT-2}$ and native rat $^{113}\text{Cd}_5\text{Zn}_2\text{MT-2}$, generated by the administration of $^{113}\text{Cd(II)}$ salt to experimental animals similarly to samples used in crystallization, were undertaken [50]. The NMR data obtained for the rat protein confirmed the cluster topology seen already with the rabbit protein (Fig. 1). Subsequently the NMR structures of $^{113}\text{Cd}_7\text{MT-2}$ from rat and rabbit livers were completed [51, 52] and those of human $^{113}\text{Cd}_7\text{MT-2}$, and, for

comparison, native $\text{Zn}_7\text{MT-2}$ were also determined [53, 54]. The NMR structures of these three homologous MTs are virtually identical, and later the crystal structure of rat $\text{Cd}_5\text{Zn}_2\text{MT-2}$ was redetermined and found to coincide very closely with the NMR structure (Fig. 2) [55, 56].

The determination of the structure of mammalian and later also of the crustacean and echinoderm MTs established the presence of trinuclear and tetranuclear thiolate clusters with divalent metal ions as the characteristic structural motif. These structural studies led to the notion about this class of proteins which include the exclusive metal coordination by cysteines, the absence of aromatic amino acids (with rare exceptions) and secondary structure. However, in recent years the biochemical characterization of bacterial and plant MTs, which differ considerably from mammalian proteins, revealed that besides high cysteine content, also aromatic amino acids, including histidine, are present. Furthermore, structural studies on these MTs revealed that apart from the trinuclear and tetranuclear clusters, also mononuclear and binuclear metal binding sites with divalent metal ions occur. In addition, in these structures a well-defined protein fold and, in some instances, metal coordination by both cysteine and histidine residues are encountered. The structural and functional properties of bacterial and plant MTs are reviewed in this special issue.

Metallothionein-3

Biological properties of metallothionein-3

In the human brain the MT-1/MT-2 and MT-3 isoforms occur [9]. The most distinctive biological property of MT-3 is its extracellular growth inhibitory activity in neuronal primary cultures, which led to its discovery [5]. Thus, MT-3, but not MT-1/MT-2 antagonizes the ability of Alzheimer disease brain extract to stimulate survival and neuritic

Fig. 1 Structure of the two metal–thiolate clusters with divalent metal ions (*gray spheres*) in mammalian $\text{M}^{\text{II}}\text{MT-2}$. The sulfur atoms (*yellow spheres*) of cysteine thiolates are labeled with the cysteine residue number





Fig. 2 The three-dimensional X-ray crystal structure of rat Zn_2Cd_5MT-2 (top) [55] and the NMR solution structure of the α -domain and β -domain of rat $^{113}Cd_7MT-2$ (bottom) [51]. The $Cd(II)$ and $Zn(II)$ ions are shown as light-orange spheres and blue spheres, respectively, connected to the protein backbone by cysteine thiolate ligands. The models were generated with PyMOL using the Protein Data Bank coordinates of 4MT2, 1MRT, and 2MRT



sprouting of cultured neurons [5, 57]. The observation that constitutive expression of MT-3 but not MT-1 inhibited the growth of cultured kidney cells under zinc-deficient conditions supports distinct functions of both isoforms [58]. The discovered bioactivity led to the hypothesis that MT-3 may be involved in pathogenic processes leading to Alzheimer disease. Independent studies supporting its role in Alzheimer disease showed that MT-3 but not MT-1/MT-2 protects neuronal cells from the toxic effect of amyloid- β ($A\beta$) peptide $A\beta_{1-40}$ [59]. However, these two effects are functionally unrelated (see below).

That MT-3 displays biological properties not observed for MT-1/MT-2 is clearly documented by *in vivo* studies in which mice overexpressing MT-3 in most organs died as a result of pancreatic atrophy, whereas expression of similar amounts of MT-1 had no effect [60]. Although the reason for MT-3 toxicity is unknown, these results provide biological evidence that the MT isoforms have different functional properties. Other *in vivo* studies supporting this conclusion showed that in a mouse model of brain injury, exogenously administered MT-3, in contrast to human MT-2, does not affect inflammation, oxidative stress, and apoptosis [61]. The latter results highlight specific and divergent roles of exogenous MT-3 when compared with the MT-1/MT-2 isoforms.

Numerous studies investigated the localization of MT-1/MT-2 and MT-3 in the CNS. MT-1 and MT-2 are present throughout the brain and spinal cord, with the astrocytes being the main cell type expressing both isoforms. In contrast, MT-3, the isoform predominantly expressed in the CNS [5], is localized in both neurons and astrocytes [10, 62, 63], where it appears to play an important role in the homeostasis of copper and zinc [9]. The MT-1/MT-2 and MT-3 isoforms have been reported to be secreted, suggesting that they may play different biological roles in the intracellular and extracellular space [64–66]. Previously, the involvement of the receptor megalin in the renal uptake of MT-1/MT-2 was described [67]. The same receptor also mediates the transport of MT-1/MT-2 into neurons following brain injury [66]. Presently, no information on whether the megalin receptor also mediates the transport of MT-3 is available.

MT-3 is present in several brain regions at different concentrations, being particularly concentrated in presynaptic terminals of zinc-enriched neurons of cerebral cortex and hippocampus. Zinc-enriched neurons belong to a subset of glutamatergic neurons and as such contain presynaptic zinc vesicles in which 10–15% of the total $Zn(II)$ in the brain is present. The colocalization of MT-3 and zinc vesicles in zinc-enriched neurons led to the suggestion that

the protein may contribute to the utilization of Zn(II) as a neuromodulator [68]. Studies of Zn₇MT-3 and zinc transporter 3 knockout mice revealed that zinc transporter 3, a transporter that concentrates Zn(II) in presynaptic vesicles, and MT-3 function in the same pathway [69]. From these studies an important role for MT-3 in the recycling of Zn(II) was suggested [70]. The demonstration of the direct interaction of Zn₇MT-3 with Rab3A, a small GTPase involved in the regulation of the synaptic vesicle cycle, supports this role [71]. The immunochemical identification of MT-3 as a component of a brain multiprotein complex with heat shock protein 84 and creatine kinase [72] suggests that MT-3 may have additional intracellular functions that remain to be elucidated. Recently, the specific and reversible binding of one extra Zn(II) to Zn₇MT-3 ($K_{\text{app}} \sim 100 \mu\text{M}$), forming Zn₈MT-3, was reported [73]. Since during synaptic signaling the free Zn(II) concentration can reach up to 300 μM [74], a reversible switch between the Zn₇MT-3 and Zn₈MT-3 forms may play a role as a zinc buffer or in an interaction with a binding partner(s). The analytical results of the latter study suggest that the reported coexistence of MT-3 species in solution with a metal distribution between five to nine M(II) per protein (M is Zn, Cd), detected by electrospray ionization (ESI) mass spectrometry (MS) upon binding of seven M(II) equivalents to apoMT-3, seems to reflect the reconstitution and ionization conditions used [75].

MT-3, like other MTs [39, 40, 76, 77], efficiently scavenges ROS. Thus, exogenous MT-3 prevents neurite extension and the death of differentiated cortical neurons caused by exposure to high oxygen concentrations, owing to its more efficient scavenging of free hydroxyl radicals than the same concentration of Zn₇MT-1/MT-2 [64]. However, studies of MT-3-null mice following damage caused by a focal cryolesion onto the cortex showed that, in contrast to MT-1/MT-2, MT-3 is unlikely to be a significant factor for controlling the inflammatory response, oxidative stress, and apoptosis after significant brain damage, but it may influence neuronal regeneration [78]. The in vitro reactions of *S*-nitrosothiols and H₂O₂ with Zn₇MT-1/MT-2 and Zn₇MT-3 revealed that whereas Zn₇MT-3 was significantly more reactive than Zn₇MT-1/MT-2 toward *S*-nitrosothiols, the reactivity of all three isoforms toward H₂O₂ was comparable. The increased reactivity of Zn₇MT-3 with free NO and *S*-nitrosothiols led to the proposal that Zn₇MT-3 may specifically convert NO signals to zinc signals [79]. The metal-induced aggregation of A β and accompanied oxidative stress contribute to the progression of Alzheimer disease (see below). In vitro studies showed that in contrast to amorphous aggregates of A β formed upon Zn(II) addition, the Zn(II) release from Zn₇MT-3 upon a slow cysteine oxidation by H₂O₂ induces fibrillar-type A β aggregates, thereby modulating its morphology. Thus, the protein may

protect cells not only by its capacity for ROS scavenging, but also through Zn(II) release and subsequent binding to A β [80]. Recently, in view of the finding that MT-3 regulates lysosomal functions, possible roles of labile zinc and Zn₇MT-3 in oxidative-stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes have been described [81]. Given the accumulating evidence that lysosomes play key roles in many neurological diseases, the role of labile zinc and Zn₇MT-3 in lysosomal function warrants further study.

As discussed above, the regulation of the basal MT-3 expression is poorly understood. Nevertheless, in recent years overexpression of MT-3 in certain cancer types including prostate [82] and breast [83] has been described. Since the *MT-3* gene was identified as hypoxia-inducible in several human tissues [84], the overexpression of MT-3 observed in several cancers presumably reflects the hypoxic conditions, due to insufficient vascularization of the fast-proliferating cancer tissue. MT-3, similarly to MT-1/MT-2, may confer cellular resistance in platinum-based chemotherapy in these cell types [85]. However, kinetics of the reaction of cisplatin with Zn₇MT-3 and Zn₇MT-2 revealed a substantially higher reactivity of cisplatin toward Zn₇MT-3 than Zn₇MT-2 [86].

Structure of metallothionein-3 with divalent metal ions

The distinct biological activity of MT-3 has been linked to the structural differences between MT-1/MT-2 and MT-3. As the structure of MTs is determined by the interplay between the polypeptide chain and metal ions, the differences in amino acid sequences ought to be responsible for the bioactivity. Compared with the amino acid sequences of mammalian MT-1/MT-2 (Table 1), the MT-3 sequence shows two inserts, an acidic hexapeptide in the C-terminal region and a threonine in position 5 in the N-terminal region followed by a conserved C₆PCP₉ motif. Structural information on the metal–thiolate clusters in M^{II}₇MT-3 was forthcoming from spectroscopic investigations of the recombinant protein and chemically synthesized single protein domains. The studies revealed the presence of two mutually interacting protein domains, with each domain encompassing a metal–thiolate cluster [87–90]. A three-metal cluster is located in the N-terminal β -domain (residues 1–31) and a four-metal cluster is located in the C-terminal α -domain (residues 32–68) of M^{II}₇MT-3 [88, 89], a metal organization found also in M^{II}₇MT-1/MT-2 (Fig. 2). From ¹¹³Cd NMR studies of human ¹¹³Cd₇MT-3, evidence for unprecedented dynamic processes within the metal–thiolate clusters was obtained [90]. From significant broadening of all ¹¹³Cd resonances and the very low and temperature-independent intensity of the Cd₃Cys₉ cluster resonances, the presence of dynamic processes acting on

two different ^{113}Cd NMR timescales was suggested: (1) fast exchange between conformational cluster substates giving rise to broad, weight-averaged resonances and (2) additional very slow exchange processes between configurational cluster substates in the β -domain. The changes in conformational substates may be visualized as minor dynamic fluctuations of the metal coordination environment and those of the configurational substates as major structural alterations brought about by temporarily breaking and reforming of the metal-thiolate bonds [90]. The existence of interchanging configurational cluster substates of comparable stability was demonstrated for inorganic adamantane-like metal–thiolate clusters with the general formula $[\text{M}_4(\text{SPh})_{10}]^{2-}$ (M is Cd(II), Zn(II), Co(II), and Fe(II)) [91]. Studies toward obtaining the 3D NMR structure of mouse and human Cd₇MT-3 have also been undertaken [92, 93]. However, because of dynamic processes in the β -domain of Cd₇MT-3, only the 3D structure of the C-terminal α -domain (residues 32–68), containing an adamantane-like Cd₄Cys₁₁ cluster, could be determined by NMR measurements. The structure of this domain reveals a peptide fold and cluster organization very similar to that found in mammalian Cd₇MT-1/MT-2, with the exception of an extended flexible loop encompassing the acidic hexapeptide insert (Fig. 3).

To account for slow dynamic events centered at the three-metal cluster of MT-3, a partial unfolding of the β -domain, whose kinetics could be determined by the *cis/trans* interconversion of Cys-Pro amide bonds in the C₆PCP₉ motif, has been suggested [94]. Support for this model came from extended X-ray absorption fine structure (EXAFS) studies of Zn₇MT-3 and its single Zn₃ β -domain where, besides evidence for the tetrahedral tetrathiolate Zn(II) coordination, also indication of an unusual structure of the three-metal cluster was obtained. In both Zn₃ β -domains a Zn···Zn backscattering at about 3.28 Å was detected (Fig. 4) [87]. Since this distance is inconsistent




Fig. 3 The NMR solution structure of the α -domain of human $^{113}\text{Cd}_7\text{MT-3}$ [93]. The Cd(II) ions are shown as light-orange spheres connected to the protein backbone by cysteine thiolate ligands. The model was generated with PyMOL using the Protein Data Bank coordinates of 2F5H




Fig. 4 Structural model of the Zn₃(Cys)₉ cluster in Zn₇MT-3 (right) and in comparison with the cyclohexane-like Zn₃(Cys)₉ cluster present in Zn₇MT-2 (left). Metal ions are shown as blue spheres connected to cysteine sulfur ligands (yellow). EXAFS: extended X-ray absorption fine structure. (Adapted with permission from [87])

with the cyclohexane-like Zn₃Cys₉ cluster structure present in the β -domain of mammalian MT-2, where a Zn···Zn distance of about 3.8 Å exists [56], it may reflect a predominant population of one cluster configuration under the conditions used (at 77 K).

Additional insights into the dynamics of the β -domain of Cd₇MT-3 were provided by molecular dynamics simulations. The simulation of the partial unfolding supported the proposed role of *cis/trans* interconversion of Cys-Pro amide bonds in the folding/unfolding process of the β -domain of Cd₇MT-3 [95]. In other molecular dynamics simulations, a correlation between the number of backbone amide hydrogen bonds to metal coordinated cysteines, NH–S^γ hydrogen bonds, in mammalian Cd₇MTs has been proposed to represent a controlling factor regulating the metal-thiolate cluster dynamics [96].

The C₆PCP₉ motif was the first segment found to be important for the extracellular growth inhibitory activity of Zn₇MT-3 [57, 94]. Mutational studies on biologically inactive Zn₇MT-1 revealed that besides the introduced C₆PCP₉ motif, also the unique Thr5 is required for the bioactivity and structure dynamics [97]. Further insights into the structural features underlying the bioactivity of Zn₇MT-3 came from a number of mutational studies which revealed that other amino acids in the β -domain along with domain–domain interactions, mediated partly through the acidic hexapeptide insert in the α -domain, are important (reviewed in [98]). Thus, although the mechanisms underlining these biological effects remain to be elucidated, the results obtained so far suggest that the structure of the β -domain of Zn₇MT-3 is subjected to a fine-tuning. Taken together, the findings of the structural and mutational studies led to the conclusion that both the specific structural features and the structure dynamics are necessary prerequisites for the extracellular biological activity of

Zn₇MT-3 [94, 97, 98]. The bioactivity in neuronal assays has been established for Cu(I)₄Zn_{3–4}MT-3 isolated from human [2] and bovine [99] brains and for recombinant human Zn₇MT-3 [98, 100]. However, comparative biological studies on well-defined metalloforms are currently lacking. Recently, two reviews focusing on various aspects of the structure and biology of MT-3 have been published [101, 102].

Structural features of Cu(I)-bound metallothionein-3

Whereas isolated mammalian MT-1 and MT-2 from livers of various species usually contain seven Zn(II), MT-3 isolated from human and bovine brains contains four Cu(I) and between three and four Zn(II). The isolated Cu(I)₄Zn_{3–4}MT-3 is a monomeric protein stable in air. EXAFS studies on Cu(I)₄Zn_{3–4}MT-3 revealed the presence of two homometallic clusters, a Cu(I)₄-thiolate cluster and a Zn_{3–4}-thiolate cluster [87]. The EXAFS data indicated that in contrast to tetrahedrally coordinated Zn(II) ions, Cu(I) ions are diagonally and/or trigonally coordinated by two or three cysteine ligands [87]. This observation, also seen for the Cu(I)-thiolate clusters in MT-1/MT-2, signifies that there are different coordination geometries for the binding of monovalent and divalent metal ions to MT-3. Therefore, to accommodate metal-thiolate clusters with different coordinating geometries, the structure should possess a high degree of flexibility.

Detailed information on the interaction of Cu(I) with MT-3 was forthcoming from spectroscopic studies of Cu(I) binding to the metal-free α -domain and β -domain and the full-length protein. The stepwise Cu(I) binding to both individual MT-3 domains showed that two well-defined Cu(I)-thiolate cluster forms are generated during this process. In the case of the β -domain (residues 1–32; Table 1), the successive formation of two cluster forms involving all nine cysteine ligands was observed, i.e., Cu₄S₉ and Cu₆S₉ clusters [88]. Similar studies on the α -domain (residues 32–68), containing 11 cysteine ligands, resulted in the formation of a Cu₄S_{8–9} cluster followed by a Cu₆S₁₁ cluster [89]. In addition, the formation of the Cu₄S₉ cluster in both the single β -domain and full-length protein was cooperative [88, 103]. The cooperative formation of a stable folding intermediate containing a Cu₄S₉ cluster in the β -domain has also been shown by ESI-MS [104]. The major differences in the respective spectroscopic features between the Cu(I)₄ and Cu(I)₆ cluster forms were observed in the low-temperature Cu(I) luminescence spectra at 77 K [88, 89, 103]. Whereas the Cu(I)₆ cluster exhibited only a single emission band at 600 nm, in the case of the Cu(I)₄ clusters two emission bands at 420 and 610 nm were discerned. The presence of two emission bands in Cu(I)₄ clusters has been correlated with short intranuclear Cu...Cu

distances (less than 2.8 Å), allowing metal-metal interactions due to a d^{10} - d^{10} orbital overlap. Accordingly, the high-energy emission band has been assigned to a ³CC (cluster-centered) origin and that at low energy to triplet charge transfer [88, 89, 105]. The metal-metal interactions may contribute to the stability of the Cu(I)₄-thiolate cluster to oxidation in air. This is supported by the observation that the expansion of the metal core, generating a Cu(I)₆-thiolate cluster, results in increased Cu...Cu distances and susceptibility to oxidation [105]. Similarities between the luminescence spectra of isolated Cu₄Zn_{3–4}MT-3 and the Cu(I)₄-thiolate cluster in the single β -domain suggested the presence of this cluster also in the isolated protein. Taken together the data indicated that the β -domain of MT-3 shows clear preference for binding of Cu(I) over Zn(II) ions.

The generation of a natively like MT-3 structure through direct Cu(I) and Zn(II) incorporation into the recombinant apoprotein revealed monomeric Cu₄Zn₄MT-3, in which, besides the Cu(I)₄ cluster in the β -domain, a Zn₄ cluster in the α -domain was present [103]. Whereas the Cu(I)₄ cluster in Cu₄Zn₄MT-3 possesses the already mentioned stability to air oxygen, the Zn₄ cluster was found to be air-sensitive. Its oxidation resulted in disulfide formation and the release of one Zn(II), yielding Cu₄Zn₃MT-3. This process could be prevented or reversed under reducing conditions [106].

Roles of metallothionein-3 in metal-linked neurodegenerative disorders

A predisposing risk factor associated with neurodegenerative diseases is age. In the normal brain a high concentration of essential transition metal ions such as zinc, copper, and iron ions is present. Dysregulated metal homeostasis, abnormal metal-protein interactions, and the associated oxidative stress, protein misfolding, and aggregation are critical common pathological hallmarks of the progression of several metal-linked neurodegenerative disorders [107, 108]. Insoluble protein deposits and diffusible oligomers are composed of individual amyloidogenic proteins or peptides such as the A β peptides, a major component of extracellular amyloid plaques in Alzheimer disease, prion protein in prion deposits typical of Creutzfeldt-Jakob disease, α -synuclein (α -Syn) in intracellular Lewy bodies in Parkinson disease, superoxide dismutase (SOD-1) aggregates in amyotrophic lateral sclerosis, and Huntington inclusions in cases of Huntington disease. In these neurodegenerative diseases, the expression of MT-3 has been found to be downregulated or altered [109–111] and changes in normal homeostasis of essential transition metals such as zinc and copper have been implicated as possible etiological factors [108, 112]. In contrast to redox-inert zinc, redox-active copper aberrantly bound to

amyloidogenic proteins can react with molecular oxygen, resulting in the production of ROS through Fenton and Haber–Weiss reactions [113]. That MT-3 may play an important role in the progression of these diseases has been reviewed [111].

A protective role of extracellular Zn₇MT-3 from Cu(II) toxicity has been suggested on the basis of investigations of its reactivity toward free Cu(II) ions [114]. The results showed that Zn₇MT-3 through Cu(II) reduction to Cu(I) by thiolate ligands and binding to the protein, forming an air-stable Cu(I)₄Zn₄MT-3 species, efficiently scavenges and redox-silences the free Cu(II) ions. In this reaction, a Cu(I)₄-thiolate cluster is formed cooperatively in the β -domain of the protein concomitant with two intramolecular disulfide bonds and the release of three Zn(II) ions [114]. Since four Zn(II) ions remained bound, the presence of an intact Zn₄ cluster in the α -domain was suggested. The formation of Cu(I)₄Zn₄MT-3 completely quenched the ascorbate-driven and Cu(II)-catalyzed production of ROS [114]. Taken together the findings indicate that two types of air-stable Cu(I)₄-thiolate clusters can be formed in the more reactive β -domain of MT-3, i.e., a fully reduced Cu(I)₄S₉ cluster and a Cu(I)₄S_{5+x} cluster. In the latter, by analogy with inorganic model complexes, the participation of a disulfide bridge sulfur (indicated by *x*) besides thiolates in the Cu(I) coordination cannot be excluded.

Studies aimed at understanding the protective effect of human Zn₇MT-3 against A β _{1–40} toxicity showed that the protein can efficiently remove copper not only from soluble A β _{1–40}-Cu(II) oligomers, but also from insoluble aggregates. In this process, Cu(II) is reduced by protein thiolates, forming the stable Cu(I)₄Zn₄MT-3 species described above and the non-redox-active A β _{1–40}-Zn(II). This metal swap completely quenches the ROS production mediated by Cu(II) bound to A β _{1–40} and occurs not only in vitro, but also in human neuroblastoma cell culture, whereby the toxic effect of A β _{1–40}-Cu(II) is abolished [115]. In recent studies, the protective effect of human Zn₇MT-2A against A β _{1–40}-Cu(II) toxicity was also investigated and compared with that of Zn₇MT-3 [116]. In neuronal cell culture, a similar protective effect has been shown. The results of the reaction between A β _{1–40}-Cu(II) and Zn₇MT-2A have been discussed together with the chemical data on the fully reduced Cu(I)₁₀MT-2A and Cu(I)₁₂MT-3 species, generated in the reaction of apoMT-2A or apoMT-3 with the Cu(I)-DTT complex under strictly reducing conditions. It has been suggested, moreover, that the increased affinity of MT-2A for Cu(I) over MT-3 makes MT-2A a better protecting agent [116]. However, as the reduction of Cu(II) in A β _{1–40}-Cu(II) to Cu(I) is accomplished by the thiolate ligands of both MTs, the formation of fully reduced Cu(I)MT-2A/MT-3 metalloforms in the oxidizing extracellular environment is highly unlikely. That under these

conditions the reaction between A β _{1–40}-Cu(II) and Zn₇MT-2A also leads to Cu(I)₄Zn₄MT-2A, in which a Cu(I)₄-thiolate cluster and two disulfide bonds are present, has been revealed (G. Meloni, C.L. Seeland, and M. Vašák, unpublished). Note also that the implicated direct metal swap between Cu(II), coordinated by nitrogen and oxygen ligands in A β _{1–40}-Cu(II), and Zn(II), coordinated by thiolate ligands in Zn₇MT-2A, without preceding Cu(II) reduction cannot occur. Consequently, the differences in Cu(I) affinity for MTs are not essential for the protective effect, but rather the long-term stability of partially oxidized Cu(I),ZnMTs formed upon Cu(II) reduction and removal from A β _{1–40}-Cu(II) in the oxidizing extracellular space are essential. The ensuing redox cycling of copper in oxygen-sensitive Cu(I),ZnMTs can change their properties from antioxidant to prooxidant. In this context it may be noted that although the MT-1/MT-2 isoforms have been found to be significantly upregulated in regions of A β plaques in the Alzheimer disease brain [117–120], the presence of substantial concentrations of Cu(II) in these plaques (0.3 mM) has been shown [108, 121]. Clearly, more studies regarding the stability of brain MTs formed in the reaction between Zn₇MTs and different concentrations of Cu(II) to molecular oxygen are needed.

Besides Alzheimer disease, a protective effect of MT-3 has also been considered in other metal-linked neurodegenerative diseases such as Parkinson disease and prion diseases [111]. Studies conducted on hemiparkinsonian rats suggest that the free-radical scavenging potency, including that of MT-3, is reduced in the Parkinson disease brain [111]. In Parkinson disease, the fibrillation and aggregation of α -Syn is a key process in the formation of intracellular inclusions, Lewy bodies, in neurons of substantia nigra pars compacta [122]. Aberrant tight binding of one Cu(II) to α -Syn and associated oxidative stress appears to contribute to the degeneration of dopaminergic neurons through the abnormal aggregation of this protein [123–125]. In prion diseases, transmitted by proteinaceous infective agents (prions) [126], the transition from natively folded prion protein (PrP^C) to misfolded prion protein (PrP^{Sc}) is a crucial pathogenic event [107, 127]. The mainly disordered part of the PrP^C structure can bind up to six Cu(II) ions [107]. Also, in this case oxidative stress, associated with the copper-catalyzed transformations of prion protein, plays an important role in the disease progression. Recent in vitro studies into the role of Zn₇MT-3 in Parkinson disease and prion diseases have shown that Zn₇MT-3, through Cu(II) removal from α -Syn and prion protein and the formation of air-stable Cu(I)₄Zn₄MT-3 species, efficiently prevents the deleterious redox activity of these proteins [128]. In view of widely different Cu(II) binding motifs in A β , α -Syn, and prion proteins, a general protective role of Zn₇MT-3 against Cu(II) toxicity in the brain can be envisaged.

Metallothionein-4

The last member of the mammalian MT gene family *MT-4* is located about 20 kb upstream from the 5' of the *MT-3* gene in both the mouse and the human genome [3]. *MT-4* consists of 62 amino acids, with an insert of glutamate in position 5 relative to the classical *MT-1* and *MT-2* proteins (Table 1). Murine *MT-4* messenger RNA appears to be present exclusively in cornified and stratified squamous epithelia. Many of these epithelia develop parakeratosis during zinc deficiency in rats. Differentiation of stratified epithelium involves movement of keratinocytes out of the basal, proliferative layer into the overlying region where synthesis of unique cytoskeletal proteins begins. In situ hybridization revealed intense labeling of *MT-4* messenger RNA in the differentiating spinous layer of cornified epithelia, whereas *MT-1* was expressed predominantly in the basal, proliferative layer. Thus, a switch in MT isoform synthesis occurs during differentiation. The *MT-4* derived from tongue epithelium contained both zinc and copper (ratio 2.6:1) [3]. From molecular and cell biology studies, involvement of *MT-4* in regulating zinc metabolism during the differentiation of stratified epithelia has been suggested [3]. Molecular biology and expression profile studies of *MT-4* in mammalian maternal decidua [129] and during epithelia development and physiology [3, 130] revealed that the *MT-4* gene is subject to a strict developmental regulation.

The function of *MT-4* in handling divalent Zn(II) or monovalent Cu(I) metal ions has been inferred from its structural properties. The organization, stability, and assembly of divalent metal ions in mammalian *MT-4* have been investigated using the Cd(II) and Co(II) metalloforms of the protein and have been compared with the well-characterized mammalian Cd₇MT-2 [131]. Both ¹¹³Cd NMR studies of reconstituted ¹¹³Cd₇MT-4 and spectroscopic characterization of Co₇MT-4 revealed that, similarly to the classical *MT-1* and *MT-2* proteins, the seven divalent metal ions are organized into two independent Cd₄Cys₁₁ and Cd₃Cys₉ clusters, with each metal ion tetrahedrally coordinated by terminal and μ -bridging cysteine ligands [131]. The cluster formation in Cd₇MT-4 was cooperative and sequential, with the Cd₄Cys₁₁ cluster in the α -domain being formed first. In addition, the metal-thiolate clusters in *MT-4* appear more stable to demetalation by EDTA than those of *MT-1* [132]. The decreased ligand substitution reactivity of EDTA observed with Cd₇MT-4 presumably reflects marked differences in the cluster geometry in Cd₇MT-4 compared with Cd₇MT-1/*MT-2* [131].

Insights into the Cu(I) binding specificity of *MT-4* have been obtained from the characterization of metalloforms upon heterologous expression of *MT-4* and its individual domains in *Escherichia coli* culture using zinc-, cadmium-,

or copper-supplemented media and their comparison with the well-characterized metalloforms of *MT-1* [133]. Spectroscopic and ESI-MS analyses of the metal composition of the purified full-length protein and the individual α - and β -domains revealed that compared with *MT-1*, the *MT-4* isoform shows an increased preference for monovalent copper ions over divalent zinc or cadmium ions, properties reflected in the formation of mixed M^I (M is Zn, Cd) and Cu(I) species [133]. On the basis of these results and the in silico protein sequence analyses, it has been concluded that *MT-4* differentiated to a MT with a “copper thionein” character rather than to a MT with a “zinc thionein” character. It has been suggested, moreover, that the dissimilarities in non-cysteine residues between *MT-4* and *MT-1* are responsible for the differences in metal binding behavior. Furthermore, the diminished Cd(II) binding ability of Cd₄- α MT-4 versus Cd₄- α MT-1 has been attributed to its high proline content, in agreement with the association of Cys-Pro motifs to structural perturbations in *MT-3* [97]. Overall, the structural studies support the role of *MT-4* in both zinc and copper metabolism in epithelia. Nevertheless, more work regarding the 3D structure of *MT-4* and its physiological role are needed.

In more recent studies, the presence of about 14 and 3 mol of sulfide (S²⁻) ligands in recombinant full-length CdMT-4 and CdMT-1, respectively, has been reported [134, 135]. This finding led to the reinterpretation of the all assumed heterometallic Zn,Cd- β MT-4 species in the previous heterologous expression of *MT-4* [133] as Cd- β MT-4 complexes that include sulfide ligands. However, although in these studies convincing analytical evidence for the presence of sulfide in these and other recombinant preparations of mammalian MTs was provided, in the analyses for MT isoforms present in the cytosol of mammalian cells and tissues by the combination of various analytical techniques, including capillary electrophoresis (CE) inductively coupled plasma MS and CE-ESI-MS, mass peaks of fully metal occupied MT isoforms without sulfide have been reported [136, 137]. Since in these studies MT isoforms containing sulfide may have escaped detection owing to their substantially increased molecular masses, more studies are needed to clarify the presence of sulfide in mammalian MTs.

Acknowledgments Parts of the work described in this review have been funded over the years by the Swiss National Science Foundation (M.V.). G.M. is a Marie Curie International Outgoing Fellow (European Commission, grant no. 252961).

References

1. Margoshes M, Vallee BL (1957) *J Am Chem Soc* 79:4813–4814
2. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M (1991) *Neuron* 7:337–347

3. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, Palmiter RD (1994) *Biochemistry* 33:7250–7259
4. Miles AT, Hawksworth GM, Beattie JH, Rodilla V (2000) *Crit Rev Biochem Mol Biol* 35:35–70
5. Masters BA, Quaife CJ, Erickson JC, Kelly EJ, Froelick GJ, Zambrowicz BP, Brinster RL, Palmiter RD (1994) *J Neurosci* 14:5844–5857
6. Coyle P, Philcox JC, Carey LC, Rofe AM (2002) *Cell Mol Life Sci* 59:627–647
7. Duncan KER, Stillman MJ (2006) *J Inorg Biochem* 100:2101–2107
8. Stillman MJ (1995) *Coord Chem Rev* 144:461–511
9. Hidalgo J, Aschner M, Zatta P, Vašák M (2001) *Brain Res Bull* 55:133–145
10. West AK, Hidalgo J, Eddins D, Levin ED, Aschner M (2008) *Neurotoxicology* 29:489–503
11. Krezel A, Hao Q, Maret W (2007) *Arch Biochem Biophys* 463:188–200
12. Henkel G, Krebs B (2004) *Chem Rev* 104:801–824
13. Cherian MG, Jayasurya A, Bay BH (2003) *Mutat Res* 533:201–209
14. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP (2004) *Histopathology* 45:103–118
15. Vašák M, Hasler DW (2000) *Curr Opin Chem Biol* 4:177–183
16. Vašák M, Romero-Isart N (2005) In: King RB (ed) *Encyclopedia of inorganic chemistry*, 2nd edn. Wiley, New York, pp 3208–3221
17. Vallee BL (1979) *Experientia Suppl* 34:19–39
18. Maliuga DP (1941) *Dokl Akad Nauk USSR* 31(2):145
19. Kägi JHR, Vallee B (1960) *J Biol Chem* 235:3460–3465
20. Kojima Y, Berger C, Vallee BL, Kägi JHR (1976) *Proc Natl Acad Sci USA* 73:3413–3417
21. Gouy M, Guindon S, Gascuel O (2010) *Mol Biol Evol* 27:221–224
22. Piscator M (1964) *Nordisk Hygienisk Tidskrift*. XLV:76–82
23. Nordberg M, Kojima Y (1979) In: Kägi JHR, Nordberg M (eds) *Metallothionein*. Birkhäuser, Basel, pp 41–116
24. Michalska AE, Choo KHA (1993) *Proc Natl Acad Sci USA* 90:8088–8092
25. Masters BA, Kelly EJ, Quaife CJ, Brinster RL, Palmiter RD (1994) *Proc Natl Acad Sci USA* 91:584–588
26. Liu Y, Liu J, Iszard MB, Andrews GK, Palmiter RD, Klaassen CD (1995) *Toxicol Appl Pharmacol* 135:222–228
27. Durnam DM, Palmiter RD (1987) *Experientia Suppl* 52:457–463
28. Palmiter RD (1998) *Proc Natl Acad Sci USA* 95:8428–8430
29. Vallee BL (1987) *Experientia Suppl* 52:5–16
30. Searle PF, Davison BL, Stuart GW, Wilkie TM, Norstedt G, Palmiter RD (1984) *Mol Cell Biol* 4:1221–1230
31. Hamer DH (1986) *Annu Rev Biochem* 55:913–951
32. West AK, Stallings R, Hildebrand CE, Chiu R, Karin M, Richards RI (1990) *Genomics* 8:513–518
33. Palmiter RD, Findley SD, Whitmore TE, Durnam DM (1992) *Proc Natl Acad Sci USA* 89:6333–6337
34. Heuchel R, Radtke F, Georgiev O, Stark G, Aguet M, Schaffner W (1994) *EMBO J* 13:2870–2875
35. Chapman GA, Kay J, Kille P (1999) *Biochim Biophys Acta* 1445:321–329
36. Udom AO, Brady FO (1980) *Biochem J* 187:329–335
37. Zeng J, Heuchel R, Schaffner W, Kägi JH (1991) *FEBS Lett* 279:310–312
38. Zeng J, Vallee BL, Kägi JH (1991) *Proc Natl Acad Sci USA* 88:9984–9988
39. Thornalley PJ, Vašák M (1985) *Biochim Biophys Acta* 827:36–44
40. Sato M, Bremner I (1993) *Free Radic Biol Med* 14:325–337
41. Vašák M (1980) *J Am Chem Soc* 102:3953–3955
42. Otvos JD, Armitage IM (1980) *Proc Natl Acad Sci USA* 77:7094–7098
43. Vašák M, Kägi JH (1981) *Proc Natl Acad Sci USA* 78:6709–6713
44. Boulanger Y, Armitage IM, Miklossy KA, Winge DR (1982) *J Biol Chem* 257:13717–13719
45. Bertini I, Luchinat C, Messori L, Vašák M (1989) *J Am Chem Soc* 111:7296–7300
46. Stillman MJ, Zelazowski AJ (1988) *J Biol Chem* 263:6128–6133
47. Good M, Hollenstein R, Sadler PJ, Vašák M (1988) *Biochemistry* 27:7163–7166
48. Frey MH, Wagner G, Vašák M, Sorensen OW, Neuhaus D, Wörgötter E, Kägi JHR, Ernst RR, Wüthrich K (1985) *J Am Chem Soc* 107:6847–6851
49. Furey WF, Robbins AH, Clancy LL, Winge DR, Wang BC, Stout CD (1986) *Science* 231:704–710
50. Vašák M, Wörgötter E, Wagner G, Kägi JH, Wüthrich K (1987) *J Mol Biol* 196:711–719
51. Schultze P, Wörgötter E, Braun W, Wagner G, Vašák M, Kägi JH, Wüthrich K (1988) *J Mol Biol* 203:251–268
52. Arseniev A, Schultze P, Wörgötter E, Braun W, Wagner G, Vašák M, Kägi JHR, Wüthrich K (1988) *J Mol Biol* 201:637–657
53. Messerle BA, Schäffer A, Vašák M, Kägi JH, Wüthrich K (1990) *J Mol Biol* 214:765–779
54. Messerle BA, Schäffer A, Vašák M, Kägi JH, Wüthrich K (1992) *J Mol Biol* 225:433–443
55. Robbins AH, McRee DE, Williamson M, Collett SA, Xuong NH, Furey WF, Wang BC, Stout CD (1991) *J Mol Biol* 221:1269–1293
56. Braun W, Vašák M, Robbins AH, Stout CD, Wagner G, Kägi JH, Wüthrich K (1992) *Proc Natl Acad Sci USA* 89:10124–10128
57. Sewell AK, Jensen LT, Erickson JC, Palmiter RD, Winge DR (1995) *Biochemistry* 34:4740–4747
58. Palmiter RD (1995) *Toxicol Appl Pharmacol* 135:139–146
59. Irie Y, Keung WM (2001) *Biochem Biophys Res Commun* 282:416–420
60. Quaife CJ, Kelly EJ, Masters BA, Brinster RL, Palmiter RD (1998) *Toxicol Appl Pharmacol* 148:148–157
61. Penkowa M, Tio L, Giralt M, Quintana A, Molinero A, Atrian S, Vašák M, Hidalgo J (2006) *J Neurosci Res* 83:974–984
62. Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C (2008) *Neurosci Lett* 438:54–58
63. Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S, Takahashi H (1996) *Brain Res* 735:257–264
64. Uchida Y, Gomi F, Masumizu T, Miura Y (2002) *J Biol Chem* 277:32353–32359
65. Lynes MA, Zaffuto K, Unfricht DW, Marusov G, Samson JS, Yin X (2006) *Exp Biol Med* (Maywood) 231:1548–1554
66. Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, Asmussen JW, Hidalgo J, Carrasco J, Leung YK, Walker AK, Fung SJ, Dunlop SA, Fitzgerald M, Beazley LD, Chuah MI, Vickers JC, West AK (2008) *J Biol Chem* 283:15349–15358
67. Klassen RB, Crenshaw K, Kozyraki R, Verroust PJ, Tio L, Atrian S, Allen PL, Hammond TG (2004) *Am J Physiol Renal Physiol* 287:F393–F403
68. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD (1997) *J Neurosci* 17:1271–1281
69. Cole TB, Robbins CA, Wenzel HJ, Schwartzkroin PA, Palmiter RD (2000) *Epilepsy Res* 39:153–169
70. Aschner M, Cherian MG, Klaassen CD, Palmiter RD, Erickson JC, Bush AI (1997) *Toxicol Appl Pharmacol* 142:229–242

71. Knipp M, Meloni G, Roschitzki B, Vašák M (2005) *Biochemistry* 44:3159–3165
72. El Ghazi I, Martin BL, Armitage IM (2006) *Exp Biol Med* (Maywood) 231:1500–1506
73. Meloni G, Polanski T, Braun O, Vašák M (2009) *Biochemistry* 48:5700–5707
74. Assaf SY, Chung SH (1984) *Nature* 308:734–736
75. Palumaa P, Eriste E, Njankova O, Pokras L, Jornvall H, Sillard R (2002) *Biochemistry* 41:6158–6163
76. Kang YJ (1999) *Proc Soc Exp Biol Med* 222:263–273
77. Liu J, Liu Y, Hartley D, Klaassen CD, Shehin-Johnson SE, Lucas A, Cohen SD (1999) *J Pharmacol Exp Ther* 289:580–586
78. Carrasco J, Penkowa M, Giralto M, Camats J, Molinero A, Campbell IL, Palmiter RD, Hidalgo J (2003) *Neurobiol Dis* 13:22–36
79. Chen Y, Irie Y, Keung WM, Maret W (2002) *Biochemistry* 41:8360–8367
80. Durand J, Meloni G, Talmard C, Vašák M, Faller P (2010) *Metallomics* 2:741–744
81. Lee SJ, Koh JY (2010) *Mol Brain* 3:30
82. Garrett SH, Sens MA, Shukla D, Nestor S, Somji S, Todd JH, Sens DA (1999) *Prostate* 41:196–202
83. Sens MA, Somji S, Garrett SH, Beall CL, Sens DA (2001) *Am J Pathol* 159:21–26
84. Tanji K, Irie Y, Uchida Y, Mori F, Satoh K, Mizushima Y, Wakabayashi K (2003) *Brain Res* 976:125–129
85. Dutta R, Sens DA, Somji S, Sens MA, Garrett SH (2002) *Prostate* 52:89–97
86. Karotki AV, Vašák M (2009) *J Biol Inorg Chem* 14:1129–1138
87. Bogumil R, Faller P, Binz PA, Vašák M, Charnock JM, Garner CD (1998) *Eur J Biochem* 255:172–177
88. Faller P, Vašák M (1997) *Biochemistry* 36:13341–13348
89. Hasler DW, Faller P, Vašák M (1998) *Biochemistry* 37:14966–14973
90. Faller P, Hasler DW, Zerbe O, Klauser S, Winge DR, Vašák M (1999) *Biochemistry* 38:10158–10167
91. Hagen KS, Stephan DW, Holm RH (1982) *Inorg Chem* 21:3928–3936
92. Öz G, Zanger K, Armitage IM (2001) *Biochemistry* 40:11433–11441
93. Wang H, Zhang Q, Cai B, Li H, Sze KH, Huang ZX, Wu HM, Sun H (2006) *FEBS Lett* 580:795–800
94. Hasler DW, Jensen LT, Zerbe O, Winge DR, Vašák M (2000) *Biochemistry* 39:14567–14575
95. Ni FY, Cai B, Ding ZC, Zheng F, Zhang MJ, Wu HM, Sun HZ, Huang ZX (2007) *Proteins* 68:255–266
96. Romero-Isart N, Oliva B, Vašák M (2010) *J Mol Model* 16:387–394
97. Romero-Isart N, Jensen LT, Zerbe O, Winge DR, Vašák M (2002) *J Biol Chem* 277:37023–37028
98. Ding ZC, Ni FY, Huang ZX (2010) *FEBS J* 277:2912–2920
99. Bruinink A, Faller P, Sidler C, Bogumil R, Vašák M (1998) *Chem Biol Interact* 115:167–174
100. Erickson JC, Sewell AK, Jensen LT, Winge DR, Palmiter RD (1994) *Brain Res* 649:297–304
101. Vašák M, Meloni G (2009) In: Sigel A, Sigel H, Sigel RKO (eds) *Metallothioneins and related chelators*. Royal Society of Chemistry, Cambridge, pp 319–351
102. Faller P (2010) *FEBS J* 277:2921–2930
103. Roschitzki B, Vašák M (2002) *J Biol Inorg Chem* 7:611–616
104. Jensen LT, Peltier JM, Winge DR (1998) *J Biol Inorg Chem* 3:627–631
105. Pountney DL, Schauwecker I, Zarn J, Vašák M (1994) *Biochemistry* 33:9699–9705
106. Roschitzki B, Vašák M (2003) *Biochemistry* 42:9822–9828
107. Gaggelli E, Kozłowski H, Valensin D, Valensin G (2006) *Chem Rev* 106:1995–2044
108. Barnham KJ, Masters CL, Bush AI (2004) *Nat Rev Drug Discov* 3:205–214
109. Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H, Ogawa N (2001) *Acta Med Okayama* 55:1–9
110. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T (2000) *Dement Geriatr Cogn Disord* 11:251–262
111. Hozumi I, Asanuma M, Yamada M, Uchida Y (2004) *J Health Sci* 50:323–331
112. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF (2006) *Trends Biochem Sci* 31:465–472
113. Halliwell B, Gutteridge JM (1984) *Biochem J* 219:1–14
114. Meloni G, Faller P, Vašák M (2007) *J Biol Chem* 282:16068–16078
115. Meloni G, Sonois V, Delaine T, Guilloureau L, Gillet A, Teissie J, Faller P, Vašák M (2008) *Nat Chem Biol* 4:366–372
116. Chung RS, Howells C, Eaton ED, Shabala L, Zovo K, Palumaa P, Sillard R, Woodhouse A, Bennett WR, Ray S, Vickers JC, West AK (2010) *PLoS One* 5:e12030
117. Adlard PA, West AK, Vickers JC (1998) *Neurobiol Dis* 5:349–356
118. Richarz AN, Bratter P (2002) *Anal Bioanal Chem* 372:412–417
119. Zambenedetti P, Giordano R, Zatta P (1998) *J Chem Neuroanat* 15:21–26
120. Carrasco J, Adlard P, Cotman C, Quintana A, Penkowa M, Xu F, Van Nostrand WE, Hidalgo J (2006) *Neuroscience* 143:911–922
121. Adlard PA, Bush AI (2006) *J Alzheimers Dis* 10:145–163
122. Dawson TM, Dawson VL (2003) *Science* 302:819–822
123. Paik SR, Shin HJ, Lee JH (2000) *Arch Biochem Biophys* 378:269–277
124. Binolfi A, Lamberto GR, Duran R, Quintana L, Bertocini CW, Souza JM, Cervenansky C, Zweckstetter M, Griesinger C, Fernandez CO (2008) *J Am Chem Soc* 130:11801–11812
125. Drew SC, Leong SL, Pham CL, Tew DJ, Masters CL, Miles LA, Cappai R, Barnham KJ (2008) *J Am Chem Soc* 130:7766–7773
126. Aguzzi A, Heikenwalder M (2006) *Nat Rev Microbiol* 4:765–775
127. Prusiner SB (1991) *Science* 252:1515–1522
128. Meloni G, Vašák M (2011) *Free Radic Biol Med* 50:1471–1479
129. Liang L, Fu K, Lee DK, Sobieski RJ, Dalton T, Andrews GK (1996) *Mol Reprod Dev* 43:25–37
130. Schlake T, Boehm T (2001) *Mech Dev* 109:419–422
131. Meloni G, Zovo K, Kazantseva J, Palumaa P, Vašák M (2006) *J Biol Chem* 281:14588–14595
132. Cai B, Zheng Q, Huang ZX (2005) *Protein J* 24:327–336
133. Tio L, Villarreal L, Atrian S, Capdevila M (2004) *J Biol Chem* 279:24403–24413
134. Capdevila M, Domenech J, Pagani A, Tio L, Villarreal L, Atrian S (2005) *Angew Chem Int Ed* 44:4618–4622
135. Tio L, Villarreal L, Atrian S, Capdevila M (2006) *Exp Biol Med* (Maywood) 231:1522–1527
136. Prange A, Profrock D (2005) *Anal Bioanal Chem* 383:372–389
137. Mounicou S, Ouerdane L, L’Azou B, Passagne I, Ohayon-Courtes C, Szpunar J, Lobinski R (2010) *Anal Chem* 82:6947–6957